Protective versus pathogenic anti-CD4 immunity: insights from the study of natural resistance to HIV infection

被引:5
作者
Burastero, Samuele E. [1 ]
Figini, Mariangela [2 ]
Frigerio, Barbara
Lusso, Paolo [3 ]
Mollica, Luca [4 ]
Lopalco, Lucia [5 ]
机构
[1] Ist Sci San Raffaele, Div Immunol Infect Dis & Transplants, Unit Clin & Mol Allergy, I-20132 Milan, Italy
[2] Fdn IRCCS Natl Inst Tumor, Dept Expt Oncol & Labs, Unit Mol Therapies, I-20132 Milan, Italy
[3] NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA
[4] Ist Sci San Raffaele, Dulbecco Telethon Inst, Biomol NMR Lab, I-20132 Milan, Italy
[5] Ist Sci San Raffaele, Div Immunol Infect Dis & Transplants, Unit Immunobiol HIV, I-20132 Milan, Italy
关键词
PROVIDE INTERMOLECULAR HELP; MONOCLONAL-ANTIBODY; RHEUMATOID-ARTHRITIS; T-CELLS; HUMORAL RESPONSES; PERIPHERAL-BLOOD; CD4; MOLECULE; FOLLOW-UP; GLYCOPROTEIN; EPITOPES;
D O I
10.1186/1479-5876-7-101
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
100103 [病原生物学]; 100218 [急诊医学];
摘要
HIV-1 exposure causes several dramatic unbalances in the immune system homeostasis. Here, we will focus on the paradox whereby CD4 specific autoimmune responses, which are expected to contribute to the catastrophic loss of most part of the T helper lymphocyte subset in infected patients, may display the characteristics of an unconventional protective immunity in individuals naturally resistant to HIV-1 infection. Reference to differences in fine epitope mapping of these two oppositely polarized outcomes will be presented, with particular reference to partially or totally CD4-gp120 complex-specific antibodies. The fine tuning of the anti-self immune response to the HIV-1 receptor may determine whether viral exposure will result in infection or, alternatively, protective immunity. Along this line, an efficacious anti-HIV strategy can rely on the active (i.e., through immunization) or passive targeting of cryptic epitopes of the CD4-gp120 complex, including those harboured within the CD4 molecule. Such epitopes are expected to be safe from genetic drift and thus allow for broad spectrum of efficacy. Moreover, since these epitopes are not routinely exposed in uninfected individuals, they are expected to become targets of neutralizing antibodies or other specifically designed molecules only after viral exposure, with a predictable low impact in terms of potentially harmful anti-CD4 self-reactivity. The experimentum naturae of naturally resistant individuals indicates a strategy to design innovative strategies to neutralize HIV-1 by acting on the sharp edge between harmful and protective self-reactivity.
引用
收藏
页数:10
相关论文
共 75 条
[1]
T-cell vaccination against anti-CD4 autoirnmunity in HIV-1 subtypes B and C-infected patients - An extended open trial [J].
Abulafia-Lapid, R ;
Mayan, S ;
Bentwich, Z ;
Keren-Zur, Y ;
Avbramovitz, Y ;
Cohen, IR ;
Atlan, H .
VACCINE, 2005, 23 (17-18) :2149-2153
[2]
Major CD4 epitopes involved in anti-CD4 T-cell autoimmunity in HIV-1 patients [J].
Abulafia-Lapid, Rivka ;
Keren-Zur, Yael ;
Yachnin, Yulia ;
Atlan, Henri .
VACCINE, 2007, 25 (16) :3192-3199
[3]
Autoimmunity, anergy, lentiviral immunity and disease [J].
Ansari, AA .
AUTOIMMUNITY REVIEWS, 2004, 3 (7-8) :530-540
[4]
INDUCTION OF TOLERANCE BY MONOCLONAL-ANTIBODY THERAPY [J].
BENJAMIN, RJ ;
WALDMANN, H .
NATURE, 1986, 320 (6061) :449-451
[5]
Development of anti-CD4 MAb hu5A8 for treatment of HIV-1 infection: preclinical assessment in non-human primates [J].
Boon, L ;
Holland, B ;
Gordon, W ;
Liu, P ;
Shiau, F ;
Shanahan, W ;
Reimann, KA ;
Fung, M .
TOXICOLOGY, 2002, 172 (03) :191-203
[6]
Autoantibodies to CD4 in HIV type 1-exposed seronegative individuals [J].
Burastero, SE ;
Gaffi, D ;
Lopalco, L ;
Tambussi, G ;
Borgonovo, B ;
DeSantis, C ;
Abecasis, C ;
Robbioni, P ;
Gasparri, A ;
Lazzarin, A ;
Celada, F ;
Siccardi, AG ;
Beretta, A .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1996, 12 (04) :273-280
[7]
BURASTERO SE, 2008, ANTIHUMAN CD4 HIV 1
[8]
BURASTERO SE, 2006, RETRIVIROLOGY S1, V3, P36
[9]
BURKLY LC, 1992, J IMMUNOL, V149, P1779
[10]
Autoimmune T-cell response to the CD4 molecule in HIV-infected patients [J].
Caporossi, AP ;
Bruno, G ;
Salemi, S ;
Mastroianni, C ;
Falciano, M ;
Salotti, A ;
Bergami, N ;
Santilio, I ;
Nisini, R ;
Barnaba, V .
VIRAL IMMUNOLOGY, 1998, 11 (01) :9-17